Cited by 1,575Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Open access

Phan, Giao Q., Yang, James C., Sherry, Richard M., Hwu, Patrick, Topalian, Suzanne L., Schwartzentruber, Douglas J., Restifo, Nicholas P., Haworth, Leah R., Seipp, Claudia A., Freezer, Linda J., Morton, Kathleen E., Mavroukakis, Sharon A., Duray, Paul H., Steinberg, Seth M., Allison, James P., Davis, Thomas A., Rosenberg, Steven A.·2003·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1533209100PMC PMC166236

Open this paper in CoChat — free account

Abstract

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a critical immunoregulatory molecule (expressed on activated T cells and a subset of regulatory T cells) capable of down-regulating T cell activation. Blockade of CTLA-4 has been shown in animal models to improve the effectiveness of cancer immunotherapy. We thus treated 14 patients with metastatic melanoma by using serial i.v. administration of a fully human anti-CTLA-4 antibody (MDX-010) in conjunction with s.c. vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). This blockade of CTLA-4 induced grade III/IV autoimmune manifestations in six patients (43%), including dermatitis, enterocolitis, hepatitis, and hypophysitis, and mediated objective cancer regression in three patients (21%; two complete and one partial responses). This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy.

Integrity signals

Registry

Crossref · 10.1073/pnas.1533209100

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,786
Self-citation
A Theory of Self-Nonself Discrimination
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,755
CTLA-4 is a second receptor for the B cell activation antigen B7.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.3.561 · Cited by 1,685
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J., Denizot, F., Luciani, M., Roux-Rouquié, M., Suzan, M., Mattéi, M., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,307

Show all 38 references

Research works printed but not linked: 4

Alegre, M. L., Frauwirth, K. A. & Thompson, C. B. (2002) Nat. Rev. Immunol. 1, 220-228.
Hurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T., Choi, E. M., Greenberg, N. M., Burg, M. B. & Allison, J. P. (2000) Cancer Res. 60, 2444-2448.10811122
Pass, H. A., Schwarz, S. L., Wunderlich, J. R. & Rosenberg, S. A. (1998) Cancer J. Sci. Am. 4, 316-323.9815296
Angelini, G., Gardella, S., Ardy, M., Ciriolo, M. R., Filomeni, G., Di Trapani, G., Clarke, F., Sitia, R. & Rubartelli, A. (2002) Proc. Natl. Acad. Sci. USA 99, 1471-1476.

Sorted by citations

Items 401–500 of 1,000

Combination of Tumor Site–Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses
Tuve, S., Chen, B., Liu, Y., Cheng, T., Touré, P. S., Sow, P. S., Feng, Q., Kiviat, N., Strauss, R., Ni, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4296 · Cited by 92
Delivery Strategies for Immune Checkpoint Blockade
Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90
High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer
Cozar, J. M., Romero, J. M., Aptsiauri, N., Vazquez, F., Vilchez, J. R., Tallada, M., Garrido, F., & Ruiz‐Cabello, F. (2007) · Human Immunology · doi:10.1016/j.humimm.2007.05.002 · Cited by 89
Aging, Cancer and Immunity
Hong, H., Wang, Q., Li, J., Liu, H. B., Meng, X., & Zhang, H. (2019) · Journal of Cancer · doi:10.7150/jca.30723 · Cited by 89
Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA-4-Dependent Manner
Zhang, T., Fresnay, S., Welty, E. E., Sangrampurkar, N., Rybak, E., Zhou, H., Cheng, X., Feng, Q., Avon, C., Laaris, A., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03624.x · Cited by 89
Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy
Thakur, N., Thakur, S., Chatterjee, S., Das, J., & Sil, P. C. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.597806 · Cited by 88
Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
Kretz-Rommel, A., Qin, F., Dakappagari, N. K., Cofiell, R., Faas, S. J., & Bowdish, K. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.699 · Cited by 88
CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria
Barnes, M. J., Griseri, T., Johnson, A. M. F., Young, W., Powrie, F. M., & Ízcue, A. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.75 · Cited by 93
Infection of CD127+(Interleukin-7 Receptor+) CD4+Cells and Overexpression of CTLA-4 Are Linked to Loss of Antigen-Specific CD4 T Cells during Primary Human Immunodeficiency Virus Type 1 Infection
Zaunders, J., Ip, S., Munier, C. M. L., Kaufmann, D., Suzuki, K., Brereton, C., Sasson, S. C., Seddiki, N., Koelsch, K. K., LANDAY, A. L., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00249-06 · Cited by 88
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
Jure‐Kunkel, M., Masters, G. R., Girit, E., Dito, G., Lee, F. Y., Hunt, J. T., & Humphrey, R. W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1451-5 · Cited by 86
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
Alard, E. L., Butnariu, A.-B., Grillo, M., Kirkham, C., Zinovkin, D. A., Newnham, L. J., Macciochi, J., & Pranjol, M. Z. I. (2020) · Cancers · doi:10.3390/cancers12071826 · Cited by 91
Potent Selection of Antigen Loss Variants of B16 Melanoma following Inflammatory Killing of MelanocytesIn vivo
Sanchez-Perez, L. A., Kottke, T. J., Díaz, R. M., Ahmed, A. U., Thompson, J., Chong, H., Melcher, A. A., Holmen, S. L., Daniels, G. A., & Vile, R. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3216 · Cited by 86
Treatment implications of the emerging molecular classification system for melanoma
Romano, E., Schwartz, G. K., Chapman, P. B., Wolchock, J. D., & Carvajal, R. D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70274-6 · Cited by 85
Histopathological and immunophenotypic features of ipilimumab‐associated colitis compared to ulcerative colitis
Adler, B. L., Pezhouh, M. K., Kim, A., Luan, L., Zhu, Q., Gani, F., Yarchoan, M. M., Chen, J., Voltaggio, L., Parian, A. M., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12744 · Cited by 85
Human Monoclonal Antibodies from Transgenic Mice
Lönberg, N. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 90
Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
CTLA-4 blockade: therapeutic potential in cancer treatments
Tarhini, A. A. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s4833 · Cited by 84
Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Nishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., Gnjatic, S., Old, L. J., & Shiku, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5839 · Cited by 84
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma
Pennock, G. K., Waterfield, W. C., & Wolchok, J. D. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318209cda9 · Cited by 84
Challenges and prospects of immunotherapy as cancer treatment
Rescigno, M., Avogadri, F., & Curigliano, G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.003 · Cited by 84
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 84
Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors
Kobayashi, T., Iwama, S., Sugiyama, D., Yasuda, Y., Okuji, T., Ito, M., Ito, S., Sugiyama, M., Onoue, T., Takagi, H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002493 · Cited by 83
Vaccination for Treatment and Prevention of Cancer in Animal Models
Cavallo, F., Offringa, R., van der Burg, S. H., Forni, G., & Melief, C. J. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90005-4 · Cited by 83
TGF-β inhibitors for the treatment of cancer
Lahn, M. M. F., Kloeker, S., & Berry, B. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.629 · Cited by 84
Cancer Immunotherapy and Nanomedicine
Sheng, W.-Y., & Huang, L. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0258-8 · Cited by 85
CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions
Lambe, T., Leung, J. C. H., Bouriez‐Jones, T., Silver, K., Makinen, K., Crockford, T. L., Ferry, H., Forrester, J. V., & Cornall, R. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3055 · Cited by 83
Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells
Ondondo, B., Jones, E., Godkin, A. J., & Gallimore, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00197 · Cited by 88
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference
Chaput, N., de Botton, S., Obéid, M., Apétoh, L., Ghiringhelli, F., Panaretakis, T., Flament, C., Zitvogel, L., & Kroemer, G. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0214-1 · Cited by 87
Immunotherapy for Advanced Melanoma
Fang, L., Lonsdorf, A. S., & Hwang, S. T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.101 · Cited by 85
MUC1 as a target antigen for cancer immunotherapy
Acres, B., & Limacher, J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.4.493 · Cited by 82
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
Comı́n-Anduix, B., Lee, Y., Jalil, J., Algazi, A. P., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-22 · Cited by 82
Immunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81
Self-citation
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Giacomo, A. M. D., Danielli, R., Calabrò, L., Bertocci, E., Nannicini, C., Giannarelli, D., Balestrazzi, A., Vigni, F., Riversi, V., Miracco, C., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0958-2 · Cited by 81
Making cold malignant pleural effusions hot: driving novel immunotherapies
Murthy, P., Ekeke, C. N., Russell, K. L., Butler, S. C., Wang, Y., Luketich, J. D., Soloff, A. C., Dhupar, R., & Lotze, M. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1554969 · Cited by 81
Depletion of CD4+CD25+ regulatory T cells enhances interleukin‐2‐induced antitumor immunity in a mouse model of colon adenocarcinoma
Imai, H., Saio, M., Nonaka, K., Suwa, T., Umemura, N., Ouyang, G., Nakagawa, J., Tomita, H., Osada, S., Sugiyama, Y., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2006.00385.x · Cited by 80
Induction of Postsurgical Tumor Immunity and T-Cell Memory by a Poorly Immunogenic Tumor
Zhang, P., Côté, A. L., de Vries, V. C., Usherwood, E. J., & Turk, M. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1264 · Cited by 81
Association of vitiligo with HLA‐A2: a meta‐analysis
Liu, J.-B., Li, M., Chen, H., Zhong, S., Yang, S., Du, W., Hao, J., Zhang, T., Zhang, X., & Zeegers, M. (2006) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2006.01899.x · Cited by 80
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00671 · Cited by 80
Durable Complete Responses With High-Dose Bolus Interleukin-2 in Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy
Tarhini, A. A., Kirkwood, J. M., Gooding, W. E., Cai, C., & Agarwala, S. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2822 · Cited by 80
Immunotherapy of melanoma: Present options and future promises
Rotte, A., Bhandaru, M., Zhou, Y., & McElwee, K. J. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9542-0 · Cited by 80
CTLA-4 (CD152): A versatile receptor for immune-based therapy
Lingel, H., & Brunner-Weinzierl, M. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101298 · Cited by 82
T cell‐mediated immunoregulation in the gastrointestinal tract
Saurer, L., & Mueller, C. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.01965.x · Cited by 81
Immune Checkpoint Inhibitors in NSCLC
Johnson, D. B., Rioth, M. J., & Horn, L. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0305-5 · Cited by 79
Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
Torino, F., Barnabei, A., Vecchis, L. D., Salvatori, R., & Corsello, S. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0404 · Cited by 79
Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti-CD28 Monovalent Fab′ Antibody
Poirier, N., Mary, C., Dilek, N., Hervouet, J., Minault, D., Blancho, G., & Vanhove, B. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04164.x · Cited by 79
Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients
Fan, Y., Du, R., Wei, F., Zhao, H., Yu, J., Wang, C., Zhan, Z., Ding, T., Ren, X., Chen, X., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1751-z · Cited by 78
Dendritic Cells in Cancer Immunotherapy
Vulink, A. J. E., Radford, K. J., Melief, C. J. M., & Hart, D. N. J. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(07)99006-5 · Cited by 80
Enrichment of CD8+ Cells From Melanoma Tumor-infiltrating Lymphocyte Cultures Reveals Tumor Reactivity for Use in Adoptive Cell Therapy
Prieto, P. A., Durflinger, K. H., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d367bd · Cited by 78
Self-citation
Immunotherapy for Melanoma: Current Status and Perspectives
Alexandrescu, D. T., Ichim, T. E., Riordan, N. H., Marincola, F. M., Nardo, A. D., Kabigting, F. D., & Dasanu, C. A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e032e8 · Cited by 80
Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
Jeong, S. D., Jung, B., Ahn, H. M., Lee, D., Ha, J., Noh, I., Yun, C., & Kim, Y. (2021) · Advanced Science · doi:10.1002/advs.202001308 · Cited by 78
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma
Byrne, K. T., Côté, A. L., Zhang, P., Steinberg, S. M., Guo, Y., Allie, R., Zhang, W., Ernstoff, M. S., Usherwood, E. J., & Turk, M. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44849 · Cited by 77
Self-citation
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy
Holmgaard, R., Brachfeld, A., Gasmi, B., Jones, D. R., Mattar, M. S., Doman, T. N., Murphy, M. Y., Schaer, D., Wolchok, J. D., & Merghoub, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151595 · Cited by 80
Immunotherapy for melanoma
Komenaka, I. K., Hoerig, H., & Kaufman, H. L. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2003.12.001 · Cited by 77
Abatacept therapy and safety management
Pham, T., Bachelez, H., Berthelot, J., Blacher, J., Claudepierre, P., Constantin, A., Fautrel, B., Gaujoux-Viala, C., Goëb, V., Gossec, L., et al. (2012) · Joint Bone Spine · doi:10.1016/s1297-319x(12)70011-8 · Cited by 76
Clinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 79
Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
Chan, L., Hwang, S. J. E., Byth, K., Kyaw, M., Carlino, M. S., Chou, S., & Fernández‐Peñas, P. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.035 · Cited by 75
Ipilimumab-induced hypophysitis: review of the literature
de Araújo, P. B., Coelho, M. C. A., Arruda, M., Gadelha, M. R., & Neto, L. V. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0301-z · Cited by 75
Recent advances in applying nanotechnologies for cancer immunotherapy
Mahjub, R., Jatana, S., Lee, S. E., Qin, Z., Pauli, G., Soleimani, M., Madadi, S., & Li, S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.010 · Cited by 76
Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 77
Colitis associated with biological agents
Freeman, H. J. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i16.1871 · Cited by 74
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
Savoia, P., Astrua, C., & Fava, P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1129478 · Cited by 81
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination
Romero, P. J., Cerottini, J., & Speiser, D. E. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0473-9 · Cited by 74
Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 78
Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response?
Groth, B. F. D. S., & LANDAY, A. L. (2008) · AIDS · doi:10.1097/qad.0b013e3282f466da · Cited by 73
Checkpoint inhibitor-induced uveitis: a case series
Conrady, C. D., Larochelle, M. B., Pecen, P. E., Palestine, A. G., Shakoor, A., & Singh, A. P. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3835-2 · Cited by 73
Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
Boasberg, P. D., Hamid, O., & O'Day, S. J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.004 · Cited by 73
Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells
Pruitt, S. K., Boczkowski, D., de Rosa, N., Haley, N. R., Morse, M. A., Tyler, D. S., Dannull, J., & Nair, S. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141383 · Cited by 75
Update on anti-CTLA-4 antibodies in clinical trials
Langer, L., Clay, T. M., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1245 · Cited by 73
Suppressive Influences in the Immune Response to Cancer
Bronte, V., & D, S. M. M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181837276 · Cited by 73
Distinctive Features of the Differentiated Phenotype and Infiltration of Tumor-Reactive Lymphocytes in Clear Cell Renal Cell Carcinoma
Wang, Q. J., Hanada, K., Robbins, P. F., Li, Y. F., & Yang, J. C.-H. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0588 · Cited by 73
Self-citation
Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2
Attia, P., Powell, D. J., Maker, A. V., Kreitman, R. J., Pastan, I. H., & Rosenberg, S. A. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000187959.45803.0c · Cited by 73
Self-citation
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Ascierto, P. A., & Kirkwood, J. M. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-62 · Cited by 73
The Human T Cell Response to Melanoma Antigens
Romero, P. J., Cerottini, J., & Speiser, D. E. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)92005-7 · Cited by 74
Current developments of immunotherapy in the clinic
Antonia, S. J., Mulé, J. J., & Weber, J. S. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.012 · Cited by 73
The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
Patel, M. A., Kim, J., Ruzevick, J., Li, G., & Lim, M. K. (2014) · Cancers · doi:10.3390/cancers6041953 · Cited by 73
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Moschella, F., Proietti, E., Capone, I., & Belardelli, F. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05464.x · Cited by 76
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
Liu, J., Blake, S. J., Smyth, M. J., & Teng, M. W. L. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.18 · Cited by 72
Nanoparticle-Delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a Treatment for Melanoma
Stone, G. W., Barzee, S., Snarsky, V., Santucci, C., Tran, B., Langer, R., Zugates, G. T., Anderson, D. G., & Kornbluth, R. S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007334 · Cited by 72
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
Vasaturo, A., Blasio, S. D., Peeters, D. G. A., de Koning, C. C. H., de Vries, I. J. M., Figdor, C. G., & Hato, S. V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00417 · Cited by 76
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
Chang, D.-K., Peterson, E., Sun, J., Goudie, C., Drapkin, R., Liu, J. F., Matulonis, U. A., Zhu, Q. K., & Marasco, W. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1090075 · Cited by 76
Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells
Hinrichs, C. S., Palmer, D. C., Rosenberg, S. A., & Restifo, N. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000177999.95831.7b · Cited by 71
Self-citation
NKG2D CAR T‐cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Spear, P., Barber, A., Rynda‐Apple, A., & Sentman, C. L. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.17 · Cited by 72
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
Rivoltini, L., Canese, P., Huber, V., Iero, M., Pilla, L., Valenti, R., Fais, S., Lozupone, F., Casati, C., Castelli, C., et al. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.463 · Cited by 74
Enhancing immune responses to tumor-associated antigens
Higgins, J. P., Bernstein, M. B., & Hodge, J. W. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.15.9133 · Cited by 77
Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients
Davis, I. D., Chen, Q., Morris, L., Quirk, J., Stanley, M. L., Tavarnesi, M. L., Parente, P., Cavicchiolo, T., Hopkins, W., Jackson, H. M., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211299.29632.8c · Cited by 71
CTLA-4 blockade and the renaissance of cancer immunotherapy
D, S. M. M., & Nitti, D. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.05.003 · Cited by 72
Identification of human tumor antigens and its implications for diagnosis and treatment of cancer
Kawakami, Y., Fujita, T., Matsuzaki, Y., Sakurai, T., Tsukamoto, M., Toda, M., & Sumimoto, H. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02182.x · Cited by 71
From T‐cell activation signals to signaling control of anti‐cancer immunity
Cronin, S. J. F., & Penninger, J. M. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00570.x · Cited by 73
IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival
Ruby, C. E., Montler, R. D., Zheng, R., Shu, S., & Weinberg, A. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2140 · Cited by 71
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
Ma, C., & Armstrong, A. W. (2013) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.813897 · Cited by 73
Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape
Bandyopadhyay, S., Quinn, T. J., Scandiuzzi, L., Basu, I., Partanen, A., Tomé, W. A., Macián, F., & Guha, C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1500541 · Cited by 74
Induction of tumor NK-cell immunity by anti-CD69 antibody therapy
Esplugues, E., Vega‐Ramos, J., Cartoixà, D., Vázquez, B. N., Salaet, I., Engel, P., & Lauzurica, P. (2005) · Blood · doi:10.1182/blood-2004-10-3854 · Cited by 73
Shared biology of GVHD and GVT effects: Potential methods of separation
Fowler, D. H. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.07.001 · Cited by 71
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70
Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells
Imai, Y., Ayithan, N., Wu, X., Yuan, Y., Wang, L. L., & Hwang, S. T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500448 · Cited by 70
Immunotherapeutic approaches for cancer therapy: An updated review
Kazemi, T., Younesi, V., Jadidi‐Niaragh, F., & Yousefi, M. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2015.1019669 · Cited by 73
Immune checkpoint receptors: homeostatic regulators of immunity
Riva, A., & Chokshi, S. (2018) · Hepatology International · doi:10.1007/s12072-018-9867-9 · Cited by 71
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 73
The paradox of T cell?mediated antitumor immunity in spite of poor clinical outcome in human melanoma
Anichini, A., Vegetti, C., & Mortarini, R. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0526-8 · Cited by 69
Association of the Cytotoxic T Lymphocyte-Associated Antigen 4 Gene with Type 1 Diabetes: Evidence for Independent Effects of Two Polymorphisms on the Same Haplotype Block
Anjos, S. M., Tessier, M.-C., & Polychronakos, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0881 · Cited by 69

Authors: Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
Surgery Branch, Laboratory of Pathology, and Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Howard Hughes Medical Institute, Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720; and Medarex, Inc., Princeton, NJ 08540
ORCID: Phan, Giao Q.
Yang, James C.
Sherry, Richard M.
Hwu, Patrick
Topalian, Suzanne L.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Steinberg, Seth M.
Allison, James P.
Davis, Thomas A.
Rosenberg, Steven A.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2003-06-25
Volume: 100
Issue: 14
Pages: 8372-8377
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1533209100
PMC: PMC166236
OpenAlex: W2134638467
Cited by: 1,575
References: 38
Citations by year: 2026: 10 · 2025: 11 · 2024: 26 · 2023: 41 · 2022: 48 · 2021: 52 · 2020: 58 · 2019: 56 · 2018: 68 · 2017: 82 · 2016: 58 · 2015: 72 · 2014: 70 · 2013: 78 · 2012: 72
FWCI: 46.70
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: CTLA-4 blockade, metastatic melanoma, autoimmunity, tumor regression, anti-CTLA-4 antibody, HLA-A*0201, cancer immunotherapy, self-tolerance, regulatory T cells, T cell activation, enterocolitis, hypophysitis, hepatitis, skin inflammation
MeSH terms: Adult, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colitis, Dermatitis, Female, Humans, Immune Tolerance, Immunotherapy, Injections, Intravenous, Injections, Subcutaneous, Lymphocyte Activation, Male, Melanoma, Membrane Glycoproteins, Middle Aged, Neoplasm Metastasis, Neoplasm Proteins, Peptide Fragments, Peptides, T-Lymphocytes, Cytotoxic, Vaccination, Vitiligo, Antigens, CD, HLA-A2 Antigen, T-Lymphocyte Subsets, Salvage Therapy, Hepatitis, Autoimmune, gp100 Melanoma Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks